A nonsteroidal selective estrogen receptor modulator that decreases bone resorption, bone loss and low density lipoprotein cholesterol in postmenopausal women.
The Post-Menopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial revealed 0.5 mg per day was associated with reduced risks of non-vertebral and vertebral fractures, ER positive breast cancer, coronary heart disease, and stroke blood increased the risk of venous thromboembolic events(ummings SR).
PEARL trial demonstrated a 42% reduction in the risk of vertebral fractures at three years, similar to observe numbers with raloxifene, estrogen therapy, oral bisphosphonates, and tibolone.
PEARL trial demonstrated decreased risk of nonvertebral fractures similar to reported studies with other antiresrptive therapies in women with osteoporosis.
This drug decreases markers of bone turnover and improves spine bone mineral density more than does raloxifene (Mclung MR).